Overview

Multiple Dose Pharmacokinetics of Intranasal Ketamine

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This is an open label, single-center study of the pharmacokinetic and safety profile of repeat doses of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Javelin Pharmaceuticals
Treatments:
Ketamine